Volume 63, Issue 3, Pages (March 2013)

Slides:

Advertisements

Similar presentations

Volume 70, Issue 2, Pages (August 2016)

Advertisements

Volume 68, Issue 4, Pages (October 2015)

Volume 58, Issue 3, Pages (September 2010)

Volume 70, Issue 3, Pages (September 2016)

Volume 71, Issue 6, Pages (June 2017)

Volume 50, Issue 1, Pages (July 2006)

Volume 51, Issue 2, Pages (February 2007)

Volume 64, Issue 3, Pages (September 2013)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Maurizio Brausi, Federica Rizzi, Saverio Bettuzzi European Urology

Volume 69, Issue 5, Pages (May 2016)

Volume 57, Issue 1, Pages (January 2010)

Volume 59, Issue 3, Pages (March 2011)

Contemporary Management of the Painful Bladder: A Systematic Review

Maintenance Bacillus Calmette-Guérin: The Standard of Care for the Prophylaxis and Management of Intermediate- and High-Risk Non–Muscle-Invasive Bladder.

Volume 49, Issue 2, Pages (February 2006)

Volume 61, Issue 5, Pages (May 2012)

Volume 69, Issue 1, Pages (January 2016)

Volume 69, Issue 5, Pages (May 2016)

Volume 69, Issue 2, Pages (February 2016)

Volume 53, Issue 5, Pages (May 2008)

Volume 71, Issue 6, Pages e171-e172 (June 2017)

Bladder Cancer: Management and Future Directions

Ashish M. Kamat, Sima Porten European Urology

Volume 51, Issue 5, Pages (May 2007)

Prostate Cancer Epidemic in Sight?

Volume 63, Issue 1, Pages (January 2013)

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Volume 52, Issue 1, Pages (July 2007)

Volume 71, Issue 6, Pages (June 2017)

Volume 74, Issue 1, Pages (July 2018)

What is New in Bladder Cancer Diagnosis and Management?

Nomograms for Bladder Cancer

Clinical Practice Recommendations for the Management of Non–Muscle Invasive Bladder Cancer Donald Lamm, Marc Colombel, Raj Persad, Mark Soloway, Andreas.

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 55, Issue 6, Pages (June 2009)

Volume 66, Issue 4, Pages (October 2014)

Volume 61, Issue 5, Pages (May 2012)

Volume 71, Issue 3, Pages (March 2017)

Volume 64, Issue 5, Pages (November 2013)

Volume 55, Issue 3, Pages (March 2009)

Clinical Practice Recommendations for the Management of Non–Muscle Invasive Bladder Cancer Donald Lamm, Marc Colombel, Raj Persad, Mark Soloway, Andreas.

Volume 65, Issue 2, Pages (February 2014)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review Sven van.

Volume 70, Issue 2, Pages (August 2016)

Volume 53, Issue 1, Pages (January 2008)

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 68, Issue 4, Pages (October 2015)

Volume 50, Issue 3, Pages (September 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Current Approaches to the Management of Non-Muscle Invasive Bladder Cancer: Comparison of Current Guidelines and Recommendations Raj Persad, Donald Lamm,

Testicular Cancer Variations in Time and Space in Europe

Maurizio Brausi, Federica Rizzi, Saverio Bettuzzi European Urology

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Prognostic Impact of Comorbidity in Patients with Bladder Cancer

Bladder Cancer: Highlights from 2006

Volume 70, Issue 1, Pages (July 2016)

Volume 75, Issue 3, Pages (March 2019)

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

Economic Burden of Bladder Cancer Across the European Union

Volume 52, Issue 4, Pages (October 2007)

Prognostic Factors in Non–Muscle-Invasive Bladder Tumors

Volume 53, Issue 6, Pages (June 2008)

Volume 51, Issue 2, Pages (February 2007)

Volume 52, Issue 1, Pages (July 2007)

Volume 54, Issue 1, Pages (July 2008)

Volume 51, Issue 5, Pages (May 2007)

Maximilian Burger, Ashish M. Kamat, David McConkey

Morgan Rouprêt, Per-Uno Malmstrom, Peter Black

Presentation transcript:

Volume 63, Issue 3, Pages 462-472 (March 2013) Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance Jorg Oddens, Maurizio Brausi, Richard Sylvester, Aldo Bono, Cees van de Beek, George van Andel, Paolo Gontero, Wolfgang Hoeltl, Levent Turkeri, Sandrine Marreaud, Sandra Collette, Willem Oosterlinck European Urology Volume 63, Issue 3, Pages 462-472 (March 2013) DOI: 10.1016/j.eururo.2012.10.039 Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 1 Consolidated Standards of Reporting Trials diagram. FD=full dose; ITT=intention to treat. European Urology 2013 63, 462-472DOI: (10.1016/j.eururo.2012.10.039) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 2 Disease-free interval by treatment group. BCG=bacillus Calmette-Guérin; df=degrees of freedom; FD=full dose; O=observed number of events. European Urology 2013 63, 462-472DOI: (10.1016/j.eururo.2012.10.039) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 3 Disease-free interval: one-third dose versus full dose. BCG=bacillus Calmette-Guérin; FD=full dose; O=observed number of events. European Urology 2013 63, 462-472DOI: (10.1016/j.eururo.2012.10.039) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 4 Disease-free interval: 1 yr of maintenance versus 3 yr of maintenance. BCG=bacillus Calmette-Guérin; O=observed number of events. European Urology 2013 63, 462-472DOI: (10.1016/j.eururo.2012.10.039) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 5 Disease-free interval: 1 yr of maintenance versus 3 yr of maintenance according to dose and risk group. HR=hazard ratio; CI=confidence interval; df=degrees of freedom. European Urology 2013 63, 462-472DOI: (10.1016/j.eururo.2012.10.039) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 6 Time to progression by treatment group. BCG=bacillus Calmette-Guérin; df=degrees of freedom; FD=full dose; O=observed number of events. European Urology 2013 63, 462-472DOI: (10.1016/j.eururo.2012.10.039) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 7 Duration of survival by treatment group. BCG=bacillus Calmette-Guérin; df=degrees of freedom; FD=full dose; O=observed number of events. European Urology 2013 63, 462-472DOI: (10.1016/j.eururo.2012.10.039) Copyright © 2012 European Association of Urology Terms and Conditions